Skip to content
DataLookout
Menu

NCT07721259

A Vaccine (STEMVAC) for Improving Survival in Patients With Triple-Negative Breast Cancer and Moderate or Extensive Residual Cancer Burden

StatusRecruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Recruitment opened
    • Start date pushed from Nov 1, 2026 to Dec 15, 2026
    • Site details revised
  2. Notable Start date: Sep 30, 2026 to Nov 1, 2026 Show 4 more changesShow less
    • Eligibility criteria expanded, about 34 words
    • Interventions: Biospecimen Collection (Procedure), CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine (Biological), Recombinant… to Biospecimen Collection (Procedure), CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine (Biological), Recombinant…
    • Secondary endpoints: details revised at 3 of 3 entries
    • Site details revised
  3. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Invasive breast cancer free survival (IBCFS)
Timeframe: Time from randomization to local or distant recurrence or death, assessed up to 3 years
Dynamics and characteristics of circulating tumor deoxyribonucleic acid (ctDNA)
Timeframe: Up to 3 weeks after last vaccination

Secondary (3)

Incidence of adverse events
Immune response
Expression of epithelial to mesenchymal transformation (EMT)-associated genes

Arms and interventions

Arm A (STEMVAC, GM-CSF)Experimental

Patients receive STEMVAC with GM-CSF ID every 3 weeks for 3 doses. Patients then receive booster vaccines ID 9 weeks after vaccine 3 and 18 weeks after booster 1. Patients also undergo collection of blood samples throughout the trial.

Arm B (GM-CSF)Active comparator

Patients receive GM-CSF ID every 3 weeks for 3 doses. Patients then receive booster vaccines ID 9 weeks after vaccine 3 and 18 weeks after booster 1. Patients also undergo collection of blood samples throughout the trial.

Biologicals: CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine

Drugs: Recombinant Granulocyte-Macrophage Colony-Stimulating Factor

Procedures: Biospecimen Collection

Sites

1 site in 1 country

  • Fred Hutch/University of Washington Cancer ConsortiumSeattle, Washington, United States